Compare Adobe Systems Inc (ADBE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Moderna, Inc. — how do they compare? Adobe Systems Inc trades at $259.87 (market cap $104.82B), while Moderna, Inc. trades at $60.42 (market cap $24.18B). The key difference: Adobe Systems Inc is far larger — about 4.3× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | MRNA | |
|---|---|---|
Market Cap | $104.82B | $24.18B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $81.80 |
52-Week Low | $193.41 | $22.36 |
Enterprise Value | $106.26B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
